ATE517125T1 - ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN - Google Patents

ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN

Info

Publication number
ATE517125T1
ATE517125T1 AT99903332T AT99903332T ATE517125T1 AT E517125 T1 ATE517125 T1 AT E517125T1 AT 99903332 T AT99903332 T AT 99903332T AT 99903332 T AT99903332 T AT 99903332T AT E517125 T1 ATE517125 T1 AT E517125T1
Authority
AT
Austria
Prior art keywords
antibodies
receptor
ßdeath
kits
diagnosis
Prior art date
Application number
AT99903332T
Other languages
English (en)
Inventor
Anan Chuntharapai
Kyung Kim
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22107878&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517125(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE517125T1 publication Critical patent/ATE517125T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99903332T 1998-01-26 1999-01-25 ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN ATE517125T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7248198P 1998-01-26 1998-01-26
PCT/US1999/001437 WO1999037684A1 (en) 1998-01-26 1999-01-25 Antibodies to death receptor 4 (dr4) and uses thereof

Publications (1)

Publication Number Publication Date
ATE517125T1 true ATE517125T1 (de) 2011-08-15

Family

ID=22107878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99903332T ATE517125T1 (de) 1998-01-26 1999-01-25 ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN

Country Status (11)

Country Link
EP (1) EP1053256B9 (de)
JP (1) JP2002500877A (de)
AT (1) ATE517125T1 (de)
AU (1) AU2338299A (de)
CA (1) CA2318405C (de)
CY (1) CY1111863T1 (de)
DK (1) DK1053256T3 (de)
ES (1) ES2368823T3 (de)
IL (1) IL137176A0 (de)
PT (1) PT1053256E (de)
WO (1) WO1999037684A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US8329179B2 (en) 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
ATE362982T1 (de) * 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
US6433147B1 (en) 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
AU4984300A (en) * 1999-05-06 2000-11-21 Vishva M Dixit Death domain containing receptor 4
WO2000073349A1 (en) * 1999-05-28 2000-12-07 Genentech, Inc. Dr4 antibodies and uses thereof
EP1658859A1 (de) * 1999-06-09 2006-05-24 Genentech, Inc. APO-2L Rezeptor-Agonist und CPT-11 Synergie-Effekt
ATE330972T1 (de) * 1999-06-09 2006-07-15 Genentech Inc Apo-2l rezeptor-agonist und cpt-11 synergie- effekt
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
US7476383B2 (en) 2000-05-02 2009-01-13 The Uab Research Foundation Antibody selective for DR4 and uses thereof
WO2002009755A2 (en) * 2000-07-27 2002-02-07 Genentech, Inc. Apo-2l receptor agonist and cpt-11 synergism
WO2002079377A2 (en) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
KR100932577B1 (ko) * 2001-05-18 2009-12-17 기린 홀딩스 가부시키가이샤 항 ｔｒａｉｌ-ｒ 항체
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
MXPA03010747A (es) * 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
WO2004016753A2 (en) * 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
JP4509570B2 (ja) * 2001-07-03 2010-07-21 ジェネンテック， インコーポレイテッド ヒトｄｒ４抗体及びその使用法
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
WO2004001009A2 (en) 2002-06-24 2003-12-31 Genentech, Inc. Apo-2 ligand/trail variants and uses thereof
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
RU2007112952A (ru) * 2004-09-08 2008-10-20 Дженентек, Инк. (Us) Способы применения лигандов рецепторов смерти и cd20-антител
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0606791A2 (pt) 2005-02-02 2010-02-09 The Uab Research Foundation métodos de reverter ou prevenir a resistência de uma célula a um agonista do receptor da morte, de triar uma célula quanto a um biomarcador da resistência a um agonista do receptor da morte, de monitorar a resistência a um agonista do receptor da morte em um indivìduo, de induzir seletivamente a apoptose em uma célula alvo expressando um receptor da morte, de tratar de um indivìduo com cáncer, de tratar de um indivìduo com uma doença inflamatória ou autoimune, de bloquear a ligação da proteìna contendo card a um receptor da morte em uma célula, de bloquear a associação de um iap com o receptor da morte e de triar um modulador de uma proteìna contendo card, composição, ácido nucleico isolado, vetor, célula, e, polipeptìdeo isolado
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
EP2379585A2 (de) 2008-10-10 2011-10-26 Anaphore, Inc. Trail-r1 und trail-r2 bindende polypeptide
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
EP3323428A1 (de) 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selektive c-flip-hemmer als antikrebsmittel
MX2022006670A (es) 2019-12-03 2023-03-17 Shanghai Jiao Tong Univ School Of Medicine Region fc de anticuerpo teniendo mayor afinidad de union al fcyriib.
EP3910331A1 (de) 2020-05-15 2021-11-17 iOmx Therapeutics AG Intrazelluläre kinase in verbindung mit resistenz gegen t-zell-vermittelte zytotoxizität und verwendungen davon
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
WO2024175554A1 (en) 2023-02-21 2024-08-29 Institut Curie Trail agonists for use in the treatment of cancer in patients having an activating alteration of fgfr3

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015698A1 (en) * 1991-03-11 1992-09-17 Sheila Drover Murine monoclonal antibodies recognizing polymorphic determinants of hla
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
SE9600820D0 (sv) * 1996-03-01 1996-03-01 Pharmacia Ab Antibodies and their use
ATE465257T1 (de) * 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
ATE486937T1 (de) * 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
ATE362982T1 (de) 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET

Also Published As

Publication number Publication date
EP1053256B1 (de) 2011-07-20
DK1053256T3 (da) 2011-10-03
CY1111863T1 (el) 2015-11-04
EP1053256B9 (de) 2012-01-18
ES2368823T3 (es) 2011-11-22
HK1033582A1 (en) 2001-09-07
PT1053256E (pt) 2011-09-28
EP1053256A1 (de) 2000-11-22
IL137176A0 (en) 2001-07-24
AU2338299A (en) 1999-08-09
CA2318405A1 (en) 1999-07-29
JP2002500877A (ja) 2002-01-15
WO1999037684A1 (en) 1999-07-29
CA2318405C (en) 2014-01-07

Similar Documents

Publication Publication Date Title
CY1111863T1 (el) Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων
EP1409544A4 (de) Humane dr4-antikörper und deren anwendungen
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
ATE465257T1 (de) Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
TR200003513T2 (tr) Pirolo[2,3d]Pirimidin kompozisyonları ve kullanımları
WO2004011611A3 (en) Taci antibodies and uses thereof
DE69501591D1 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
NO20061736L (no) Krystallform av epotilon B
ATE354655T1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
BR0107691A (pt) Sapogeninas substituìdas e seu uso
DK0960107T3 (da) 6-Thiosubstituerede paclitaxeler
DE69528710D1 (de) 2-substituierte 1,2,5-thiadiazolidin-3-on-1,1-dioxiden, zusammensetzung und deren verwendung
DE69919179D1 (de) Substituierte gamma-phenyl-delta-lactone und deren analoge, und ihre verwendungen
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
ATE395363T1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
TR200000291T2 (tr) Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
DE69612056D1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.
DE69841260D1 (de) Bakterielle pheromone und deren verwendungen
ATE189897T1 (de) Antikörper gegen das prorenin profragment, reninaktive substanz die diese enthält und prorenintest die diese verwendet
DE50004023D1 (de) 1,4-dioxacycloalkan-2-one und 1,4-dioxacycloalken-2-one

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1053256

Country of ref document: EP